gyrA and gyrB mutations are implicated in cross-resistance to Ciprofloxacin and moxifloxacin in Clostridium difficile (Q39657922)

13 September 2017

gyrA and gyrB mutations are implicated in cross-resistance to Ciprofloxacin and moxifloxacin in Clostridium difficile (English)

1 reference

13 September 2017

Clostridium difficile

0 references

1 reference

Larbi Dridi

1

1 reference

13 September 2017

Jacques Tankovic

2

1 reference

13 September 2017

Béatrice Burghoffer

3

1 reference

13 September 2017

Frédéric Barbut

4

1 reference

13 September 2017

Jean-Claude Petit

5

1 reference

13 September 2017

language of work or name

English

0 references

publication date

1 November 2002

1 reference

13 September 2017

4

1 reference

Antimicrobial Agents and Chemotherapy

inferred from page(s)

published in

1 reference

13 September 2017

46

1 reference

13 September 2017

11

1 reference

13 September 2017

3418-3421

1 reference

Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in gyrA.

13 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=128732

In vitro activity of new quinolones against Clostridium difficile

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=128732

Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=128732

Comparison of PCR-ribotyping, arbitrarily primed PCR, and pulsed-field gel electrophoresis for typing Clostridium difficile

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=128732

Roles of gyrA mutations in resistance of clinical isolates and in vitro mutants of Bacteroides fragilis to the new fluoroquinolone trovafloxacin

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=128732

Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=128732

Effects of mutations in GrlA of topoisomerase IV from Staphylococcus aureus on quinolone and coumarin activity

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=128732

Complete Genome Sequence of Treponema pallidum, the Syphilis Spirochete

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=128732

Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=128732

The complete genome sequence of the gastric pathogen Helicobacter pylori

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=128732

In vitro activity of BAY 12-8039, a new fluoroquinolone

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=128732

Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=128732

Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=128732

Relapse of antibiotic associated colitis: endogenous persistence of Clostridium difficile during vancomycin therapy

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=128732

Mutations in gyrA gene of quinolone-resistant Salmonella serotypes isolated from humans and animals

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=128732

Use of an enzyme-linked immunoassay for Clostridium difficile serogrouping

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=128732

Clostridium difficile colitis

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=128732

Single or double mutational alterations of gyrA associated with fluoroquinolone resistance in Campylobacter jejuni and Campylobacter coli

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=128732

In vitro activity of sitafloxacin against Clostridium difficile

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=128732

Comparative in vitro activity of BAY 12-8039 and five other antimicrobial agents against anaerobic bacteria

21 August 2018

1 reference

12 December 2020

Comparative in vitro activity of moxifloxacin against Gram-positive clinical isolates

1 reference

12 December 2020

Analysis of the mutations involved in fluoroquinolone resistance of in vivo and in vitro mutants of Escherichia coli

1 reference

12 December 2020

Treatment of Clostridium difficile infection

1 reference

12 December 2020

Mechanisms of fluoroquinolone resistance

1 reference

12 December 2020

In vitro activity of new generation fluoroquinolones against genotypically distinct and indistinguishable Clostridium difficile isolates

1 reference

12 December 2020

10.1128/AAC.46.11.3418-3421.2002

Identifiers

DOI

1 reference

release_zp7kozb4ojgfzozgitilij7niq

13 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/zp7kozb4ojgfzozgitilij7niq

24 November 2022

mapped directly with Wikidata item

1 reference

13 September 2017

1 reference